ESPOO, Finland, April 13, 2016 -- Based on the previously announced resolution of the Board of Directors to issue shares held by the Company, 93 954 Nokia shares (NOKIA) were today transferred to participants of Nokia's equity-based incentive plans as settlement in accordance with the plan rules.
About Nokia
Nokia is a global leader in the technologies that connect people and things. Powered by the innovation of Bell Labs and Nokia Technologies, the company is at the forefront of creating and licensing the technologies that are increasingly at the heart of our connected lives.
With state-of-the-art software, hardware and services for any type of network, Nokia is uniquely positioned to help communication service providers, governments, and large enterprises deliver on the promise of 5G, the Cloud and the Internet of Things. www.nokia.com
Media Enquiries:
Nokia
Communications
Tel. +358 (0) 10 448 4900
Email: [email protected]
HUG#2003056


California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
FDA Approves Mitapivat for Anemia in Thalassemia Patients
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



